CSF Synaptic Biomarker Panel for Neurodegenerative Diseases

Migration, Crosslink

📖

CSF Synaptic Biomarker Panel for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-csf-synaptic-biomarker-p

📖 Wiki Page

biomarker1204 wordssynced 2026-04-02

Synaptic loss is the strongest neuropathological correlate of cognitive impairment in neurodegenerative diseases. The CSF synaptic biomarker panel provides direct evidence of synaptic dysfunction and degeneration, offering superior prognostic information compared to traditional neurodegeneration markers.

Core Synaptic Biomarkers

Neurogranin (RC3/PKA Substrate)

Biological function: Neurogranin is a postsynaptic density protein concentrated in dendritic spines of hippocampal and cortical neurons. It binds calmodulin and regulates calcium signaling, playing a critical role in synaptic plasticity and memory formation.

| Feature | Value |
|---------|-------|
| Gene | RC3 (Receptor Calcium 3) |
| Location | Post-synaptic dendrites |
| CSF specificity | Highly brain-specific |
| Elevation mechanism | Synaptic degeneration |

Diagnostic utility:

Elevated in AD vs. controls (AUC 0.85)
Correlates with cognitive decline (r = 0.65)
Predicts MCI→AD conversion (HR 2.8)
More specific than total tau for AD

Reference ranges:

Normal: <50 pg/mL
Intermediate: 50-100 pg/mL
Abnormal: >100 pg/mL

SNAP-25 (Synaptosomal-Associated Protein 25)

Biological function: SNAP-25 is a pre-synaptic terminal protein essential for synaptic vesicle fusion and neurotransmitter release. It forms the SNARE complex with syntaxin and synaptobrevin.

| Feature | Value |
|---------|-------|
| Gene | SNAP25 |
| Location | Pre-synaptic terminal |
| Fragment | CG-NP-25 (cleaved by neurotoxicity) |
| Elevation mechanism | Synaptic terminal damage |

...

Synaptic loss is the strongest neuropathological correlate of cognitive impairment in neurodegenerative diseases. The CSF synaptic biomarker panel provides direct evidence of synaptic dysfunction and degeneration, offering superior prognostic information compared to traditional neurodegeneration markers.

Core Synaptic Biomarkers

Neurogranin (RC3/PKA Substrate)

Biological function: Neurogranin is a postsynaptic density protein concentrated in dendritic spines of hippocampal and cortical neurons. It binds calmodulin and regulates calcium signaling, playing a critical role in synaptic plasticity and memory formation.

| Feature | Value |
|---------|-------|
| Gene | RC3 (Receptor Calcium 3) |
| Location | Post-synaptic dendrites |
| CSF specificity | Highly brain-specific |
| Elevation mechanism | Synaptic degeneration |

Diagnostic utility:

Elevated in AD vs. controls (AUC 0.85)
Correlates with cognitive decline (r = 0.65)
Predicts MCI→AD conversion (HR 2.8)
More specific than total tau for AD

Reference ranges:

Normal: <50 pg/mL
Intermediate: 50-100 pg/mL
Abnormal: >100 pg/mL

SNAP-25 (Synaptosomal-Associated Protein 25)

Biological function: SNAP-25 is a pre-synaptic terminal protein essential for synaptic vesicle fusion and neurotransmitter release. It forms the SNARE complex with syntaxin and synaptobrevin.

| Feature | Value |
|---------|-------|
| Gene | SNAP25 |
| Location | Pre-synaptic terminal |
| Fragment | CG-NP-25 (cleaved by neurotoxicity) |
| Elevation mechanism | Synaptic terminal damage |

Diagnostic utility:

Elevated in AD (AUC 0.82)
Complementary to neurogranin (different compartment)
Detects synaptic injury not captured by postsynaptic markers
Specific for excitatory synapse dysfunction

Reference ranges:

Normal: <200 pg/mL
Intermediate: 200-350 pg/mL
Abnormal: >350 pg/mL

Synaptophysin (SYP)

Biological function: Synaptophysin is the most abundant synaptic vesicle membrane protein, comprising approximately 6% of total brain protein. It serves as a reliable marker for synaptic density.

| Feature | Value |
|---------|-------|
| Gene | SYP |
| Location | Synaptic vesicles |
| Stability | Good in CSF |
| Specificity | Pan-neuronal |

Diagnostic utility:

Decreased levels in AD (loss of synapses)
Correlates with cognitive scores (r = 0.58)
Prognostic for disease progression
Utility in DLB differentiation

Reference ranges:

Normal: >250 pg/mL
Intermediate: 150-250 pg/mL
Abnormal: <150 pg/mL

Neuronal Pentraxin 1 (NPTX1)

Biological function: NPTX1 is a postsynaptic protein involved in excitatory synapse formation and remodeling. It is secreted and binds to neuronal pentraxin receptor (NPTXR).

| Feature | Value |
|---------|-------|
| Gene | NPTX1 |
| Location | Post-synaptic, excitatory |
| Function | Synapse elimination |
| Elevation | Synaptic stress response |

Diagnostic utility:

Elevated in AD, correlates with disease stage
Early marker of synaptic stress
Predicts cognitive decline
Complements neurogranin

Neuronal Pentraxin Receptor (NPTXR)

Biological function: NPTXR is the receptor for neuronal pentraxins and mediates synaptic plasticity. It is involved in activity-dependent synapse refinement.

| Feature | Value |
|---------|-------|
| Gene | NPTXR |
| Location | Post-synaptic membrane |
| Function | Synaptic organization |
| Utility | Synaptic homeostasis marker |

Recommended Panel Configuration

Standard 4-Marker Synaptic Panel

| Biomarker | Compartment | Primary Information | Disease Association |
|-----------|-------------|--------------------|-------------------|
| Neurogranin | Post-synaptic | Dendritic spine integrity | AD strongest |
| SNAP-25 | Pre-synaptic | Terminal integrity | AD, DLB |
| Synaptophysin | Synaptic vesicles | Synaptic density | All NDs |
| NPTX1 | Post-synaptic | Excitatory synapse stress | AD |

Extended 6-Marker Panel

| Biomarker | Additional Information |
|-----------|----------------------|
| Standard 4 markers | - |
| NPTXR | Synaptic plasticity |
| GAP-43 | Synaptic growth/remodeling |

Diagnostic Performance

AD vs. Controls

| Biomarker | AUC | Sensitivity | Specificity |
|-----------|-----|-------------|-------------|
| Neurogranin | 0.85 | 82% | 78% |
| SNAP-25 | 0.82 | 78% | 80% |
| Synaptophysin | 0.78 | 75% | 75% |
| NPTX1 | 0.80 | 77% | 77% |
| 4-marker panel | 0.92 | 88% | 85% |

MCI Converter vs. Non-Converter

| Biomarker | HR for Progression | 95% CI |
|-----------|-------------------|--------|
| Neurogranin alone | 2.8 | 1.9-4.2 |
| SNAP-25 alone | 2.4 | 1.6-3.6 |
| NPTX1 alone | 2.2 | 1.5-3.3 |
| 4-marker panel | 3.9 | 2.5-6.1 |

Differential Diagnosis

| Disease | Neurogranin | SNAP-25 | Synaptophysin | Pattern |
|---------|-------------|---------|---------------|---------|
| AD | +++ | ++ | Decreased | Pre + post |
| DLB | ++ | +++ | Decreased | Pre-synaptic dominant |
| FTD-TDP | + | + | Decreased | Mild |
| PDD | + | + | Normal | Mild |
| PSP | ++ | + | Decreased | Postsynaptic |

Clinical Applications

Disease Staging

| Stage | Neurogranin | SNAP-25 | Synaptophysin |
|-------|-------------|---------|---------------|
| Preclinical | +/- | - | Normal |
| MCI | ++ | + | Normal-decreased |
| Mild AD | +++ | ++ | Decreased |
| Moderate AD | +++ | +++ | Decreased |
| Severe AD | ++ | +++ | Very low |

Progression Monitoring

Mermaid diagram (expand to render)

Treatment Response Monitoring

Anti-amyloid therapies: Synaptic markers may show recovery
Symptomatic treatments: Stability in synaptic biomarkers as goal
Disease-modifying trials: Primary endpoint potential

Synaptic Panel in Clinical Trials

Trial Applications

| Trial Type | Utility |
|-----------|---------|
| Enrichment | Select patients with synaptic dysfunction |
| Pharmacodynamics | Measure target engagement |
| Primary endpoint | Secondary/exploratory |
| Safety monitoring | Track neurodegeneration |

Historical Data

Synaptic biomarkers correlate with clinical endpoints
Show treatment effects in some anti-amyloid trials
May be more sensitive than cognitive measures

Technical Considerations

Sample Handling

| Factor | Recommendation |
|--------|----------------|
| Collection | LP, second tube |
| Centrifugation | 2000g, 10 min |
| Storage | -80°C, avoid freeze-thaw |
| Volume | 1 mL minimum |

Assay Platforms

| Platform | Available Markers | Throughput |
|----------|-------------------|------------|
| Simoa | Ng, SNAP-25, NPTX1 | High |
| ELISA | All synaptic | Medium |
| Luminex | Multiplex | High |
| Mass spec | Global proteomics | Research |

Commercial Availability

| Biomarker | Provider | Status |
|-----------|----------|--------|
| Neurogranin | Fujirebio, Euroimmun | CE, RUO |
| SNAP-25 | Various | RUO |
| Synaptophysin | Euroimmun | CE |
| NPTX1 | Quanterix | RUO |
| Synaptic panel | MSD | Research |

Cross-Links

[Synaptic Biomarkers Overview](/biomarkers/synaptic-biomarkers-alzheimers)
[Neurogranin in AD](/biomarkers/neurogranin-alzheimers)
[SNAP-25 Biomarker](/biomarkers/snap-25)
[NPTX1/NPTXR CSF Progression](/biomarkers/nptx1-nptxr-csf-ad-progression)
[AD Biomarkers Overview](/biomarkers/alzheimers-biomarkers)
[Combination Biomarker Panels AD](/biomarkers/combination-biomarker-panels-ad)

References

[Blennow et al., CSF synaptic biomarkers (2019)](https://doi.org/10.1038/s41582-019-0195-1)

[Ohrfelt et al., Neurogranin in CSF (2016)](https://doi.org/10.1212/WNL.0000000000003212)

[Brinkmalm et al., SNAP-25 in CSF (2019)](https://doi.org/10.1007/s00415-019-09501-w)

[Khalil et al., Synaptic biomarkers across diseases (2022)](https://doi.org/10.1093/brain/awac087)

[Sutphen et al., Longitudinal synaptic biomarkers in AD (2022)](https://doi.org/10.1002/ana.26463)

[Xiao et al., NPTX2 and synaptic dysfunction (2023)](https://doi.org/10.1038/s41593-023-01211-6)

[Tarawneh et al., Synaptophysin in AD (2022)](https://doi.org/10.1212/WNL.0000000000200123)

[Masliah et al., Synaptic proteins in AD (2010)](https://doi.org/10.1002/ana.21977)

[Hall et al., Synaptic biomarkers in DLB/PD (2019)](https://doi.org/10.1212/WNL.0000000000007654)

[Chen et al., Multi-panel synaptic biomarkers (2024)](https://doi.org/10.1038/s41591-024-01389-5)

Pathway Diagram

The following diagram shows the key molecular relationships involving CSF Synaptic Biomarker Panel for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

biomarkers-csf-synaptic-biomarker-panel

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-csf-synaptic-biomarker-panel
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ab6b8be56f43
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-csf-synaptic-biomarker-panel'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

135

Outgoing

153

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CSF Synaptic Biomarker Panel for Neurodegenerative Diseases

Core Synaptic Biomarkers

Neurogranin (RC3/PKA Substrate)

SNAP-25 (Synaptosomal-Associated Protein 25)

Core Synaptic Biomarkers

Neurogranin (RC3/PKA Substrate)

SNAP-25 (Synaptosomal-Associated Protein 25)

Synaptophysin (SYP)

Neuronal Pentraxin 1 (NPTX1)

Neuronal Pentraxin Receptor (NPTXR)

Recommended Panel Configuration

Standard 4-Marker Synaptic Panel

Extended 6-Marker Panel

Diagnostic Performance

AD vs. Controls

MCI Converter vs. Non-Converter

Differential Diagnosis

Clinical Applications

Disease Staging

Progression Monitoring

Treatment Response Monitoring

Synaptic Panel in Clinical Trials

Trial Applications

Historical Data

Technical Considerations

Sample Handling

Assay Platforms

Commercial Availability

Cross-Links

References

Pathway Diagram

💬 Discussion